Pennsylvania’s short-term politics threaten its biotech future, driving innovation and opportunity to rival states.

Pfizer is now focusing on revving up its pipeline as CEO Albert Bourla sets his sights on an extra $20 billion in revenue by ...

The U.S. Food and Drug Administration is yet to authorize the two modified boosters, for which applications were submitted ...

Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Multiple people across the globe who stepped forward are speaking about what they say is the debilitating aftermath they now ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

DelveInsight's Oropharyngeal Cancer Market Insights report includes a comprehensive understanding of current treatment ...

Get the latest stock market update and key takeaways in healthcare, including Pfizer, Amgen, Novo Nordisk results, and obesity drug bidding wars.

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Moderna beats Q3 forecasts as cost-cutting offsets weaker COVID vaccine sales and new mRNA cancer trials advance.

Johnson & Johnson said on Thursday it has asked U.S. health regulators to authorize its single-dose COVID-19 vaccine for ...

Pfizer Inc said on Monday its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against the pandemic.